This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonnema, S. J. Articles by Hegedüs, L. Search for Related Content PubMed PubMed Citation Articles by Bonnema, S. J. Articles by Hegedüs, L.

Propylthiouracil before ¹³¹I Therapy of Hyperthyroid Diseases: Effect on Cure Rate Evaluated by a Randomized Clinical Trial

Departments of Endocrinology and Metabolism (S.J.B., F.N.B., L.H.) and Nuclear Medicine (A.V., J.M.), Odense University Hospital, DK-5000 Odense, Denmark

Address all correspondence and requests for reprints to: Dr. Steen J. Bonnema, Department of Endocrinology and Metabolism, Odense University Hospital, DK-5000 Odense C, Denmark. E-mail: steen.bonnema{at}dadlnet.dk.

A randomized clinical trial was performed to clarify whether pretreatment with propylthiouracil (PTU) before radioiodine (¹³¹I) therapy influences the final outcome of this therapy, as has been indicated by retrospective studies. Untreated consecutive hyperthyroid patients with Graves’ disease (n = 23) or a toxic nodular goiter (n = 57) were randomized to either PTU (+PTU; n = 39) or no pretreatment (–PTU; n = 41) before compensated ¹³¹I therapy. The median PTU dose was 100 mg, which was discontinued 4 d before treatment. The median ¹³¹I activity was 302 MBq (range, 87–600 MBq). After ¹³¹I therapy, the serum free T₄ index increased in the +PTU group from 97.7 ± 47.5(±SD) nmol/liter at the time of therapy to 152.3 ± 77.6 nmol/liter at 3 wk (P < 0.001) and 140.4 ± 75.9 nmol/liter at 6 wk (P < 0.001). In the –PTU group, the serum free T₄ index, which was initially 254.3 ± 145.7 nmol/liter, decreased significantly to 212.0 ± 113.0 nmol/liter at 3 wk (P < 0.05) and 165.8 ± 110.0 nmol/liter at 6 wk (P < 0.005). After 1 yr of follow-up, the treatment failure rate in patients with a toxic nodular goiter was four times higher in the +PTU group than in the –PTU group (nine of 20 vs. three of 25 patients; P = 0.06), whereas the difference among patients with Graves’ disease was less obvious (four of six vs. four of nine; P = 0.81). Patients in the +PTU group who were cured had higher serum TSH (s-TSH) levels at the time of ¹³¹I therapy than those who were not cured. By adjusting for a possible interfactorial relationship through a regression analysis, including the s-TSH level and type of disease, only PTU pretreatment had a significant adverse effect on the cure rate (P = 0.03). In conclusion, this randomized trial demonstrates that PTU pretreatment reduces the cure rate of ¹³¹I therapy in hyperthyroid diseases, although this adverse effect seems to be attenuated by the concomitant rise in s-TSH.

This article has been cited by other articles:

				S. Fast, V. E. Nielsen, P. Grupe, S. J. Bonnema, and L. Hegedus Optimizing 131I Uptake After rhTSH Stimulation in Patients with Nontoxic Multinodular Goiter: Evidence from a Prospective, Randomized, Double-Blind Study J. Nucl. Med., May 1, 2009; 50(5): 732 - 737. [Abstract] [Full Text] [PDF]

				S. Fast, V. E. Nielsen, S. J. Bonnema, and L. Hegedus Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy Eur. J. Endocrinol., April 1, 2009; 160(4): 517 - 528. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, V. E. Nielsen, H. Boel-Jorgensen, P. Grupe, P. B. Andersen, L. Bastholt, and L. Hegedus Improvement of Goiter Volume Reduction after 0.3 mg Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with a Very Large Goiter: A Double-Blinded, Randomized Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3424 - 3428. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, F. N. Bennedbaek, A. Veje, J. Marving, and L. Hegedus Continuous Methimazole Therapy and Its Effect on the Cure Rate of Hyperthyroidism Using Radioactive Iodine: An Evaluation by a Randomized Trial J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2946 - 2951. [Abstract] [Full Text] [PDF]

				Radioiodine therapy for hyperthyroidism DTB, June 1, 2006; 44(6): 44 - 48. [Abstract] [Full Text] [PDF]

				B. E Jensen, S. J Bonnema, and L. Hegedus Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease Eur. J. Endocrinol., July 1, 2005; 153(1): 15 - 21. [Abstract] [Full Text] [PDF]

				D. S. Cooper Antithyroid Drugs N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917. [Full Text] [PDF]

				L. Bartalena, F. Bogazzi, A. Pinchera, and E. Martino Treatment with Thionamides before Radioiodine Therapy for Hyperthyroidism: Yes or No? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1256 - 1256. [Full Text] [PDF]

				S. J. Bonnema and L. Hegedus Authors' Response: Treatment with Thionamides before Radioiodine Therapy for Hyperthyroidism: Yes or No? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1256 - 1257. [Full Text] [PDF]